Presentation TCT 2017 ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Gregg W. Stone October 31, 2017
Presentation TCT 2017 ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Stephen G. Ellis October 31, 2017
Presentation TCT 2017 Featured Lecture: The NIH Mission to Enhance DIVERSITY in Clinical Trials, Education, and the Workforce Presenter: Roxana Mehran, George A. Mensah October 31, 2017
Presentation TCT 2017 Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE Presenter: Robert A. Harrington, Sanjay Kaul, Schuyler Jones October 30, 2017
Presentation TCT 2017 Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations) Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh October 30, 2017
Presentation TCT 2017 Amulet: Data Synthesis and Ongoing Trials Presenter: William A. Gray, Vivek Y. Reddy, Fabian Nietlispach October 30, 2017
Presentation TCT 2017 Clinical Trials Using RAPID: Some POC Thoughts Presenter: Schuyler Jones, Hiroyoshi Yokoi, Theodore Heise October 30, 2017
Presentation TCT 2017 WATCHMAN: Data Synthesis and Ongoing Trials Presenter: William A. Gray, Vivek Y. Reddy October 30, 2017
Presentation TCT 2017 Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions? Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson October 30, 2017
Presentation TCT 2017 Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud October 30, 2017
Presentation TCT 2017 Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions? Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber October 30, 2017
Presentation TCT 2017 Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of Women Presenter: Wayne B. Batchelor, George A. Mensah, Roxana Mehran October 30, 2017
Presentation TCT 2017 Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of African American/Latina Populations Presenter: Wayne B. Batchelor, George A. Mensah October 30, 2017
Presentation TCT 2017 Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: SCAI Presenter: Wayne B. Batchelor, George A. Mensah, Cindy L. Grines October 30, 2017
Presentation TCT 2017 Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: STS/AATS Presenter: Wayne B. Batchelor, George A. Mensah, Vinod H. Thourani October 30, 2017
Presentation TCT 2017 Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: AHA Presenter: Wayne B. Batchelor, George A. Mensah, Robert A. Harrington October 30, 2017
Presentation TCT 2017 Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: ACC Presenter: Wayne B. Batchelor, George A. Mensah, Pamela S. Douglas October 30, 2017
Presentation TCT 2017 FDA Perspectives: Diversity in Clinical Trials and its Impact of Device Evaluation Presenter: Wayne B. Batchelor, George A. Mensah, Christopher J Popma October 30, 2017
Presentation TCT 2017 Office, Home, or Ambulatory Blood Pressure: How to Measure Blood Pressure in Practice and Clinical Trials Presenter: Sidney C. Smith, Michael A. Weber, C. Venkata S. Ram October 30, 2017
Presentation TCT 2017 How to Interpret Trials That Are Stopped Early (eg, PRAMI, FAME II, DECISION CTO, and Others) Presenter: Roxana Mehran, Robert W. Yeh, Laura Mauri October 30, 2017